United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets, usp are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions:   - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablets. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic thera

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 6.25 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets, usp are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablets. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy.

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4 ), clinical studies (14.1 )]. carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2) ]. carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4 )]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see  drug interactions (7.2) ]. carvedilol is contraindicated in the following conditions: risk summary available data regarding use of carvedilol in pregnant wo

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 3.125 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

United States - English - NLM (National Library of Medicine)

proficient rx lp - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4) , clinical studies (14.1)] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: risk summary available data regarding use of carvedilol in pregna

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals inc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see clinical studies (14.1)]. carvedilol tablet is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies ( 14.2 ) ]. carvedilol tablet is indicated for the management of essential hypertension [see clinical studies ( 14.3 , 14.4 ) ]. it can be used alone or in combination with other antihypertensive agents, especially thiazide- type diuretics [see drug interactions   ( 7.2 ) ]. carvedilol tablet is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmati

United States - English - NLM (National Library of Medicine)

st. mary's medical park pharmacy - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 25 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see  drug interactions (7.4) , clinical studies (14.1) ] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see